BHUBANESWAR: The New Year seems to have ushered in a major breakthrough for thalassaemia patients with the US Food and Drug ...

Vanda also sells sleep disorder drug Hetlioz, which reached the market in 2014, and relapsing multiple sclerosis treatment Ponvory, which was approved in 2021. The FDA is scheduled on Jan. 7 to decide ...

Approval was based on the phase 3 ENERGIZE and ENERGIZE-T studies evaluating the safety and efficacy of mitapivat in adults with alpha- or beta-thalassemia.

Detailed price information for Agios Pharmaceuticals (AGIO-Q) from The Globe and Mail including charting and trades.

CAMBRIDGE, Mass. - The U.S. Food and Drug Administration has approved AQVESME (mitapivat), an oral pyruvate kinase activator, for the treatment of anemia in adults with alpha- or beta-thalassemia, ...

AB Science receives US patent for masitinib to treat sickle cell disease: Paris Friday, December 26, 2025, 14:00 Hrs [IST] AB Science SA, a pharmaceutical company specializing in ...

Agios Pharmaceuticals wins FDA approval for Aqvesme in alpha- and beta-thalassemia, making mitapivat the only approved option, despite a new REMS.

A case report described a woman with endometrial cancer in India with an extremely rare blood group type, complicating blood ...

Abstract: LiDAR and camera are two important sensors for 3D object detection in autonomous driving. Despite the increasing popularity of sensor fusion in this field, the robustness against inferior ...